pemrametostat (GSK3326595) / Ipsen  >>  Phase 2
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
pemrametostat (GSK3326595) / Ipsen
OTT-19-06, NCT04676516: A Phase II Window of Opportunity Trial of PRMT5 Inhibitor, GSK3326595, in Early Stage Breast Cancer

Completed
2
40
Canada
GSK3326595, PRMT5 inhibitor
Ottawa Hospital Research Institute, Ontario Institute for Cancer Research, GlaxoSmithKline, London Regional Cancer Program, Canada, Hamilton Health Sciences Corporation
Breast Cancer
08/22
08/22
NCT03614728: Study to Investigate the Safety and Clinical Activity of GSK3326595 and Other Agents to Treat Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)

Terminated
1/2
30
Canada, US
GSK3326595, 5-Azacitidine
GlaxoSmithKline
Neoplasms
01/22
01/22

Download Options